Susanna M. I. Goorden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Susanna M. I. Goorden has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- André B. P. van Kuilenburg
Amsterdam UMC, Vrije Universiteit Amsterdam, Laboratory Genetic Metabolic Diseases Amsterdam the Netherlands
1 shared publication Annet M. Bosch
Amsterdam UMC location University of Amsterdam
1 shared publication- C. Khya S. Snelder
Department of Endocrinology and Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands
1 shared publication - Carla E. M. Hollak
Department of Endocrinology and Metabolism Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands
1 shared publication Désirée Y. van Haaften-Visser
Centre for Lysosomal and Metabolic Diseases, Department of Paediatrics, Erasmus University Medical Center, Rotterdam, the Netherlands
1 shared publicationElly Bogaerts
Centre for Lysosomal and Metabolic Diseases, Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 19 July 2025
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 146 (1-2) , 109194
Two new cases of KYNU deficiency: Further delineation of the phenotypic and biochemical spectrum and exploration of treatment options
- 19 July 2025
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 146 (1-2) , 109194
Open AccessTwo new cases of KYNU deficiency: Further delineation of the phenotypic and biochemical spectrum and exploration of treatment options
- 27 July 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (10) , 1272-1282
Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels
Background: Fabry disease is a very heterogeneous X-linked lysosomal storage disease. Disease manifestations in the kidneys, heart, and brain vary greatly, even between patients of the same sex and with the same disease classification (classical or nonclassical). A biomarker with a strong association with the development of disease manifestations is needed to determine the need for Fabry-specific treatment and appropriate frequency of follow-up because clinical manifestations of the disorder may take decennia to develop. Methods: We investigated the levels of plasma lysoGb3 levels over time and its association with disease manifestations and disease course in 237 untreated patients with Fabry disease (median age 42 years, 38% male) using linear mixed-effect models. Results: LysoGb3 levels are stable over time in plasma of untreated patients with Fabry disease. Higher levels of lysoGb3 were associated with steeper decline in eGFR (P = 0.05) and a faster increase in albuminuria (measured as the urinary albumin-to-creatinine ratio, P < 0.001), left ventricular mass (measured on echocardiography, P < 0.001), left atrial volume index (P = 0.003), and Fazekas score (P = 0.003). In addition, regardless of age, higher lysoGb3 levels were associated with higher relative wall thickness (P < 0.001) and unfavorable functional markers on echocardiography, including septal mitral annular early diastolic velocity (e′, P < 0.001) and the ratio of early transmitral velocity (E) to e′ (E/e′, P = 0.001). Conclusions: In an individual patient with Fabry disease, the plasma lysoGb3 level reached a specific level in early childhood which, in the absence of Fabry-specific treatment, remained stable throughout life. The level of lysoGb3 in untreated patients was associated with nearly all Fabry-specific disease manifestations, regardless of the sex of the patient.
- 27 July 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (10) , 1272-1282
Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels
Background: Fabry disease is a very heterogeneous X-linked lysosomal storage disease. Disease manifestations in the kidneys, heart, and brain vary greatly, even between patients of the same sex and with the same disease classification (classical or nonclassical). A biomarker with a strong association with the development of disease manifestations is needed to determine the need for Fabry-specific treatment and appropriate frequency of follow-up because clinical manifestations of the disorder may take decennia to develop. Methods: We investigated the levels of plasma lysoGb3 levels over time and its association with disease manifestations and disease course in 237 untreated patients with Fabry disease (median age 42 years, 38% male) using linear mixed-effect models. Results: LysoGb3 levels are stable over time in plasma of untreated patients with Fabry disease. Higher levels of lysoGb3 were associated with steeper decline in eGFR (P = 0.05) and a faster increase in albuminuria (measured as the urinary albumin-to-creatinine ratio, P < 0.001), left ventricular mass (measured on echocardiography, P < 0.001), left atrial volume index (P = 0.003), and Fazekas score (P = 0.003). In addition, regardless of age, higher lysoGb3 levels were associated with higher relative wall thickness (P < 0.001) and unfavorable functional markers on echocardiography, including septal mitral annular early diastolic velocity (e′, P < 0.001) and the ratio of early transmitral velocity (E) to e′ (E/e′, P = 0.001). Conclusions: In an individual patient with Fabry disease, the plasma lysoGb3 level reached a specific level in early childhood which, in the absence of Fabry-specific treatment, remained stable throughout life. The level of lysoGb3 in untreated patients was associated with nearly all Fabry-specific disease manifestations, regardless of the sex of the patient.